Analysts' downgrade of Relay Therapeutics' revenue estimates...
Analysts' downgrade of Relay Therapeutics' revenue estimates and prediction of an accelerated decline in revenues compared to industry average growth rate suggest a bearish outlook. The unchanged price target implies business performance in line with expectations despite downward sales forecast adjustment.
Revenue Downgrade: Here's What Analysts Forecast For Relay Therapeutics, Inc. (NASDAQ:RLAY)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment